MURALI  CHINTAGUMPALA  to  Cranial Irradiation
                            
                            
                                This is a "connection" page, showing publications  MURALI  CHINTAGUMPALA  has written about  Cranial Irradiation.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.835
         
        
        
     
 
    
        
        - 
            Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. Cancer. 2011 Feb 01; 117(3):635-41.
            
            
                Score: 0.331
            
         
        
        - 
            A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol. 2009 Feb; 11(1):33-40.
            
            
                Score: 0.288
            
         
        
        - 
            Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1445-50.
            
            
                Score: 0.080
            
         
        
        - 
            Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006 Oct; 7(10):813-20.
            
            
                Score: 0.063
            
         
        
        - 
            White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol. 2004 Nov 15; 22(22):4551-60.
            
            
                Score: 0.055
            
         
        
        - 
            Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008 Aug 01; 26(22):3749-55.
            
            
                Score: 0.018